Inactivation of Viruses during Ultraviolet Light Treatment of Human Intravenous Immunoglobulin and Albumin

Hart, H.; Reid, K.; Hart, W.

doi:10.1159/000462316

Cited by 12 publications

(10 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is interesting to compare plasma protein data with those achieved using other procedures, such as methylene blue (MB) and illumination [32] or SD treatment [33]. Those, as well as others under development [34][35][36][37][38][39], affect the content in labile plasma proteins to different extents. For instance, plasma leucofiltration and MB induce losses of 26-32% of FVIII, 13-39% FXI, 23-26% fibrinogen, 10% FV, 16% FXIII and 18% vWF activity [40,41].…”

Section: Discussionmentioning

confidence: 99%

Nanofiltration of single plasma donations: feasibility study

Burnouf¹,

Radosevich²,

El‐Ekiaby³

et al. 2003

Vox Sanguinis

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Nanofiltration of single plasma donations: feasibility study

Burnouf¹,

Radosevich²,

El‐Ekiaby³

et al. 2003

Vox Sanguinis

View full text Add to dashboard Cite

show abstract

“…However, this method is only effective if the liquid is clear or the irradiation dose can be adjusted. UVC has also been employed to sterilize plasma and plasma derivates [9][10][11]. It is, however, strongly quenched in turbid or protein-containing solutions.…”

Section: Active Principlementioning

confidence: 99%

UVC Irradiation for Pathogen Reduction of Platelet Concentrates and Plasma

Seltsam

Müller²

2011

Transfus Med Hemother

104

147

View full text Add to dashboard Cite

Besides the current efforts devoted to microbial risk reduction, pathogen inactivation technologies promise reduction of the residual risk of known and emerging infectious agents. A novel pathogen reduction process for platelets, the THERAFLEX UV-Platelets system, has been developed and is under clinical evaluation for its efficacy and safety. In addition, proof of principle has been shown for UVC treatment of plasma units. The pathogen reduction process is based on application of UVC light of a specific wavelength (254 nm) combined with intense agitation of the blood units to ensure a uniform treatment of all blood compartments. Due to the different absorption characteristics of nucleic acids and proteins, UVC irradiation mainly affects the nucleic acid of pathogens and leukocytes while proteins are largely preserved. UVC treatment significantly reduces the infectivity of platelet units contaminated by disease-causing viruses and bacteria. In addition, it inactivates residual white blood cells in the blood components while preserving platelet function and coagulation factors. Since no photoactive compound needs to be added to the blood units, photoreagent-related adverse events are excluded. Because of its simple and rapid procedure without the need to change the established blood component preparation procedures, UVC-based pathogen inactivation could easily be implemented in existing blood banking procedures.

show abstract

“…Inactivation by UVC may be of interest for the manufacture of some fragile or large proteins. Inactivation of enveloped and nonenveloped viruses was also achieved (45)(46)(47)(48)(49). The design of state-of-the-art UVC devices was recently described (50,51).…”

Section: Ultraviolet Cmentioning

confidence: 99%

Virus Safety of Intravenous Immunoglobulin: Future Challenges

Boschetti

Stucki

Späth

et al. 2005

CRIAI

View full text Add to dashboard Cite

Patients with immunodeficiencies or some types of autoimmune diseases are dependent on safe therapy with intravenous immunoglobulins. State-of-the-art manufacturing processes provide a high safety standard by incorporating virus elimination procedures into the manufacturing process. Based on their mechanism, these procedures are grouped into three classes: partitioning, inactivation, and removal based on size. Because of current socioeconomic and ecological changes, emerging pathogens continue to be expected. Such pathogens may spread very quickly because of increased intercontinental traffic. Severe acute respiratory syndrome-coronavirus and the West Nile virus are recent examples. Currently, it is not possible to predict the impact such a pathogen will have on blood safety because the capacity for a globally coordinated reaction to such a threat is also evolving. The worst-case scenario would be the emergence of a transmissible, small, nonenveloped virus in the blood donor population. Examples of small nonenveloped viruses, which change host and tissue tropism, are discussed, with focus on parvoviridae. Although today's immunoglobulins are safer than ever, in preparation for future challenges it is a high priority for the plasma industry to proactively investigate such viruses on a molecular and cellular level to identify their vulnerabilities.

show abstract

Inactivation of Viruses during Ultraviolet Light Treatment of Human Intravenous Immunoglobulin and Albumin

Cited by 12 publications

References 23 publications

Nanofiltration of single plasma donations: feasibility study

Nanofiltration of single plasma donations: feasibility study

UVC Irradiation for Pathogen Reduction of Platelet Concentrates and Plasma

Virus Safety of Intravenous Immunoglobulin: Future Challenges

Contact Info

Product

Resources

About